Perspectives in the development of hybrid bifunctional antitumour agents

Abstract

In spite of the development of a large number of novel target-specific antitumour agents, the single-agent therapy is in general not able to provide an effective durable control of the malignant process. The limited efficacy of the available agents (both conventional cytotoxic and novel target-specific) reflects not only the expression of defence mechanisms, but also the complexity of tumour cell alterations and the redundancy of survival pathways, thus resulting in tumour cell ability to survive under stress conditions. A well-established strategy to improve the efficacy of antitumour therapy is the rational design of drug combinations aimed at achieving synergistic effects and overcoming drug resistance. An alternative strategy could be the use of agents designed to inhibit simultaneously multiple cellular targets relevant to tumour growth/survival. Among these novel agents are hybrid bifunctional drugs, i.e. compounds resulting by conjugation of different drugs or containing the pharmocophores of different drugs. This strategy has been pursued using various conventional or target-specific agents (with DNA damaging agents and histone deacetylase inhibitors as the most exploited compounds). A critical overview of the most representative compounds is provided with emphasis on the HDAC inhibitor-based hybrid agents. In spite of some promising results, the actual pharmacological advantages of the hybrid agents remain to be defined. This commentary summarizes the recent advances in this field and highlights the pharmacological basis for a rational design of hybrid bifunctional agents.

Essential Role of DNA Methyltransferase 1–mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors

“…The diverse heterogeneity of genetic and molecular alterations observed in cancer cells and their ability to compensate the perturbed pathways in response to drug treatment likely account for drug resistance, either de novo or acquired (42, 43). In this work, we have provided evidence that activation of the IGF-1R pathway through transcriptional upregulation of IGF2 via DNMT1-mediated hypermethylation of the H19/IGF2 ICR play a key role in both de novo and acquired resistance to HDIs.…”

Natural Products and Chemical Biology Tools: Alternatives to Target Epigenetic Mechanisms in Cancers

“…Moreover, looking closely, the multi‐target effect of natural products can be a real advantage for therapeutic treatments. Multi‐target molecules have been recently highly studied in several pathology such as pain management, diabetic cardiomyopathy, cancer,, and mostly Alzheimer's disease . Therefore multi‐target therapies using natural products can be an alternative for epigenetic treatment of cancers as long as their mechanisms of action remain well controlled and understood.…”

Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation

“…Combining CYP51 inhibition characteristics with bioreduction properties of a nitro-group in one molecule may offer a better solution in drug development against Chagas disease and other trypanosomatid-induced diseases. This strategy has been successfully used in numerous occasions, including drugs for cancer, asthma and chronic obstructive pulmonary disease as well as neurodegenerative diseases [19][20][21][22].…”